Nexplanon (etonogestrel implant) / Organon - LARVOL DELTA

Three Concurrent Nonpalpable Nexplanon Implants in the Upper Arms Following Presumed Failed Insertions: A Case Report. (PubMed, Case Rep Obstet Gynecol) - "This case is unique in demonstrating the cumulative consequence of repeated misinterpretation of nonpalpability as failed insertion, resulting in multiple retained devices across both upper arms. It highlights a critical gap in procedural verification and reinforces the importance of standardized postinsertion confirmation protocols."

Journal • Long-acting Reversible Contraceptives

Dual Intrauterine Device Placement for Refractory Endometriosis Pain in a Bicornuate Uterus: A Case Report. (PubMed, Cureus) - "She had failed treatment with an etonogestrel implant and dienogest. Dual LNG-IUS insertion under hysteroscopic guidance represents a minimally invasive and effective strategy for managing endometriosis-related pain in patients with a bicornuate uterus when conventional therapies are inadequate. Long-term follow-up and regular monitoring are warranted to assess for potential side effects."

Journal • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Musculoskeletal Pain • Pain • Women's Health

Etonogestrel contraceptive implant as emergency contraception: a mechanism of action pharmacodynamic pilot study. (PubMed, Contraception) - P4 | "An etonogestrel contraceptive implant is a potential option for an emergency contraception method. Because this study only evaluated a small sample, further research is needed to evaluate suppression in different BMI groups."

Journal • PK/PD data • Long-acting Reversible Contraceptives

Risk of ischemic and hemorrhagic stroke in users of progestogen-only contraceptives: A Danish registry study. (PubMed, Contraception) - "POCs-including POPs, implants, injections, and LNG-IUDs-were not associated with an increased risk of either IS or ICH and support their use as appropriate alternatives to CHCs with ethinylestradiol for women in whom stroke risk is an important clinical consideration."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke • Long-acting Reversible Contraceptives

Norethindrone Reduced Prolonged Bleeding Related to Etonogestrel Implant. (PubMed, Am Fam Physician) - No abstract available

Journal

Etonogestrel Implant as Emergency Contraception (clinicaltrials.gov) - P4 | N=12 | Recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date

Two cases of pregnancy during the fourth year of 68 mg etonogestrel implant use. (PubMed, Eur J Contracept Reprod Health Care) - "These cases suggest that both intrauterine and ectopic pregnancies can occur in year four of ENG implant use. Further work should be conducted to determine risk factors for implant failure, especially in years four and five of use."

Journal • Long-acting Reversible Contraceptives

Comparison of topical ethyl chloride spray and subcutaneous 1% mepivacaine for local anesthesia in single-rod etonogestrel implant insertion: an observational study. (PubMed, Front Med (Lausanne)) - "Pre-procedural nervousness was the only variable showing a significant, though weak, association with higher pain levels (rho = 0.23; p < 0.01). Ethyl chloride spray was associated with shorter anesthetic application time and lower procedural resource use without increasing perceived pain, suggesting that it may enhance procedural efficiency and support workflow optimization in high-demand reproductive healthcare settings."

Journal • Observational data • Anesthesia • Long-acting Reversible Contraceptives • Pain • Psychiatry

How painful is Implanon NXT® insertion?: A multicenter randomized trial on the use of Acetaminophen, Mefenamic Acid and Diclofenac Sodium for pain management post Implanon NXT® insertion. (PubMed, BMC Womens Health) - "All oral analgesics demonstrated a reduction in pain score. Based on this limited study, the most suitable analgesic for pain management post Implanon NXT® insertion is tablet Mefenamic Acid 250 mg twice daily for up to 2 days. More robust double-blinded studies using placebos as a control are needed to confirm this finding."

Journal • Pain

Dissociation of gonadal and adrenal androgens one year after etonogestrel implant insertion. (PubMed, Eur J Contracept Reprod Health Care) - "One year after ENG implant insertion, deep LH suppression was accompanied by parallel reduction of gonadal androgens (total and free testosterone) and SHBG, whereas oestradiol, AMH, and adrenal DHEA-S were essentially unchanged, indicating a dissociation between suppressed gonadal and preserved adrenal androgens. The reduced-bleeding phenotype was not accompanied by differential hormonal change."

Journal • Long-acting Reversible Contraceptives

Contraception Use and Patterns in Liver Compared to Kidney Transplant Recipients: An Analysis Using Real World Data (ATC 2026) - "Contraceptive exposures included progestin-only pills (POPs), combined hormonal contraceptives (CHCs), medroxyprogesterone injections (Depot), etonogestrel implants, hormonal intrauterine devices (IUDs), copper IUDs (Cu-IUD), and emergency contraception (EC). Only one in four reproductive-aged female SOT recipients received contraception. Progestin-based methods dominated initial therapy selection and demonstrated the greatest stability, with significantly fewer switches than CHCs, though medroxyprogesterone use was notably higher than expected. These findings demonstrate an opportunity to improve proactive, transplant-specific contraceptive care pathways."

Clinical • Real-world • Real-world evidence • Gynecology • Long-acting Reversible Contraceptives • Solid Organ Transplantation • Transplantation

Fluoroscopy-guided removal of a migrated non-palpable implanon adherent to the ulnar nerve: a case report. (PubMed, Front Med (Lausanne)) - "We report the case of a 33-year-old left-handed woman who presented with persistent abnormal bleeding 3 years post-etonogestrel implant placement...By the 2-week follow-up visit, the incision had healed well, and the patient reported that the transient tingling sensation-which had occurred intraoperatively due to minimal traction during the final dissection-had completely resolved. Fluoroscopy-guided implant removal is effective for the removal of deeply placed or migrated implants, particularly when conventional methods fail; however, accurate localization and referral to specialists are essential for their safe removal."

Journal • Long-acting Reversible Contraceptives

Contraception Use and Preferences Among Individuals Experiencing Homelessness Reached Through a Menstrual Health Street Medicine Team. (PubMed, J Health Care Poor Underserved) - "Unhoused individuals reported different contraceptive patterns from the general population and preferred licensed providers for contraceptive care. Transportation and cost were the primary barriers to accessing care."

Journal • Long-acting Reversible Contraceptives

Safety and effectiveness of etonogestrel implant in Chinese women requiring contraception: a multicenter, prospective, observational study. (PubMed, Arch Gynecol Obstet) - "Safety findings from this study in China's real-world clinical setting were consistent with the clinical development program without unexpected safety signals. Observed contraceptive effectiveness was consistent with established evidence for the implant, with general satisfaction reported among Chinese women."

Journal • Observational data • Long-acting Reversible Contraceptives

SCD CURE: Effects of the Contraceptive Implant in Women With Sickle Cell Disease (clinicaltrials.gov) - P4 | N=22 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Hematological Disorders • Long-acting Reversible Contraceptives • Sickle Cell Disease

Immediate vs Delayed Postpartum Implanon-NXT (clinicaltrials.gov) - P=N/A | N=90 | Not yet recruiting | Sponsor: Assiut University

Adverse events • New trial • Hematological Disorders • Postpartum Hemorrhage

Progestin-only implant and breast cancer risk in adolescents and premenopausal women: A systematic review and meta-analysis. (ASCO 2026) - "Background: Progestin-only long-acting reversible contraception via subdermal etonogestrel implants (Implanon/Nexplanon) is widely used... In large, contemporary population-based observational studies excluding hereditary breast cancer predisposition cohorts, use of etonogestrel/progestin-only subdermal implants is consistently associated with a modestly increased risk of incident breast cancer (~23%) compared with non-use. While the absolute risk increase is likely small in younger women, the consistent signal across study designs supports its relevance for individualized risk–benefit discussions and shared contraceptive counseling in routine clinical practice."

Retrospective data • Review • Breast Cancer • Long-acting Reversible Contraceptives • Oncology • Solid Tumor • BRCA1 • BRCA2

Clinical Effects of the U.S. Food and Drug Administration's Newest Restrictions on the Etonogestrel Implant. (PubMed, Obstet Gynecol) - "Although the intent was to maintain safe practices for device insertion and removal, the large body of long-standing safety data should raise questions about the need for these new requirements. In the absence of safety concerns regarding device insertion and removal, a REMS requirement on the etonogestrel contraceptive implant may lead to decreased reproductive health care access and provision."

Journal • Long-acting Reversible Contraceptives

Bleeding Patterns after Replacing versus Extending the Use of the Contraceptive Implant at Three Years of Use. (PubMed, Contraception) - "Clinicians can counsel patients that short-term bleeding patterns are not expected to change meaningfully when replacing or extended use of contraceptive implant at three years."

Journal • Long-acting Reversible Contraceptives

Intravascular migration of a subdermal etonogestrel implant to the pulmonary artery: A case report. (PubMed, Radiol Case Rep) - "The patient remained asymptomatic and declined endovascular or surgical retrieval, opting for conservative management with clinical and imaging follow-up. This case highlights the importance of extending imaging beyond the insertion site in patients with non-palpable contraceptive implants and emphasizes the role of chest radiography and CT pulmonary angiography in accurately localizing migrated devices."

Journal • Long-acting Reversible Contraceptives

Barriers and reasons for initiating the use of long-acting reversible contraceptives (LARC) in a cohort of Brazilian women. (PubMed, Women Health) - "Among the 1,193 women 965 (81.2%) choose the levonorgestrel 52 mg IUD, whereas 43 (3,6%) chose the etonogestrel implant, and 164 (13,79%) the copper-IUD...Social disparities, limited availability, lack of trained health care hinder awareness and access to LARCs. In conclusion, the key barriers identified were the lack of availability of preferred LARC methods in public healthcare facilities and the considerable delay between a woman's decision to use contraception and its actual initiation."

Journal • Long-acting Reversible Contraceptives • Women's Health

Evaluation of the impact of etonogestrel implant use on women's sexuality and quality of life. (PubMed, Women Health) - "The etonogestrel contraceptive implant did not alter women's sexual function, and its adverse effects did not impact their overall quality of life. The method was well accepted by the participants."

HEOR • Journal • Long-acting Reversible Contraceptives

Etonogestrel implant as back-up in patients primarily using a combined oral contraceptive pill: A multi-center trial (ACOG 2026) - "From August 2020 to March 2023, we enrolled 120 participants, including 31 (26%) new-start and 89 (74%) current COC users. Ninety-six (80%) participants completed the 12-month exit visit. Most study discontinuations occurred for lost-to-follow-up (LTFU) (18 [15%]) or consent withdrawal (4 [3%])."

Clinical

Contraceptive-Induced Weight Gain-Myth and Reality Review. (PubMed, Life (Basel)) - "The etonogestrel implant occupies a complex middle ground...For the minority of women carrying this variant, the implant may trigger clinically significant weight gain, suggesting a biological basis for their subjective experience despite statistical evidence. Ultimately, the persistence of the weight gain concern is fueled by the nocebo effect and the misattribution of natural age-related weight trajectories to contraceptive use."

Journal • Review • Endometriosis • Gynecology • Polycystic Ovary Syndrome • Women's Health • ER

Progesterone Hypersensitivity, an Uncommon Cause of Dermatitis after Etonogestrel Implant Removal (AACE 2026) - "She subsequently transitioned to drospirenone-ethinyl estradiol combined oral contraceptive and discontinued cabergoline. Timing is a critical clue: flares usually occur during the luteal phase of the menstrual cycle when progesterone levels rise, with improvement following the onset of menses as progesterone declines. Known triggers for progesterone hypersensitivity"

Cough • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases